To discuss or comment on this announcement please visit our Investor Hub.
To discuss or comment on this announcement please visit our Investor Hub.
Race Oncology CEO Phillip Lynch and CSO Dr Daniel Tillett present Race’s June 2022 Quarterly Investor Briefing followed by a Q&A session.
30 June 2022 – Race Oncology Limited (“Race”) is pleased to share further interim results from our preclinical cardioprotection program in collaboration with researchers from the University of Newcastle (ASX announcement: 28 April 2021). This program aimed at exploring the…
28 June 2022 – Race Oncology Limited (“Race”) is pleased to share the final results from our preclinical melanoma research program in collaboration with the University of Newcastle (ASX announcement: 19 March 2021). This program aimed to explore the use…
22 June 2022 – Race Oncology Limited (“Race”) is pleased to share further interim results from its preclinical melanoma research program (ASX announcement: 19 March 2021). The program’s objective was to explore the use of Zantrene® (bisantrene dihydrochloride) in novel…
21 June 2022 – Race Oncology Limited (“Race”) is pleased to announce that two peer reviewed research poster abstracts detailing new preclinical data on the anti-cancer uses of Zantrene (also known as bisantrene or CS1) have been published in the…